Clinical Trial Results:
A Phase 2, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MEDI3506 in Adult Participants with Uncontrolled Moderate-to-severe Asthma
Summary
|
|
EudraCT number |
2020-000789-40 |
Trial protocol |
HU DE |
Global end of trial date |
06 Feb 2023
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
28 Dec 2023
|
First version publication date |
28 Dec 2023
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
D9181C00001
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04570657 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
AstraZeneca AB
|
||
Sponsor organisation address |
151 85, Södertälje, Sweden,
|
||
Public contact |
Global Clinical Lead, AstraZeneca, information.center@astrazeneca.com
|
||
Scientific contact |
Global Clinical Lead, AstraZeneca, information.center@astrazeneca.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
06 Feb 2023
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
06 Feb 2023
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective of the study was to assess the effect of tozorakimab (MEDI3506) compared with placebo on lung function, in adult participants with uncontrolled moderate-to-severe asthma.
|
||
Protection of trial subjects |
This study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with International Council for Harmonisation Good Clinical Practice, applicable regulatory requirements and the AstraZeneca policy on Bioethics.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
17 Sep 2020
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Argentina: 87
|
||
Country: Number of subjects enrolled |
Germany: 27
|
||
Country: Number of subjects enrolled |
Hungary: 21
|
||
Country: Number of subjects enrolled |
Poland: 33
|
||
Country: Number of subjects enrolled |
South Africa: 16
|
||
Country: Number of subjects enrolled |
United Kingdom: 2
|
||
Country: Number of subjects enrolled |
United States: 49
|
||
Worldwide total number of subjects |
235
|
||
EEA total number of subjects |
81
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
235
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||||||||||||||||
Recruitment details |
Participants were enrolled and randomised in 52 study centres in 7 countries including Argentina, Germany, Hungary, Poland, South Africa, the United Kingdom, and the United States from 17 September 2020. The last participant completed their last study visit on 06 February 2023. | ||||||||||||||||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||||||||||||||||
Screening details |
Adult participants with uncontrolled moderate to severe asthma were randomised in a 1:1:1 ratio to receive tozorakimab Dose A (lower dose), tozorakimab Dose B (higher dose), or placebo. Of the 478 participants screened, 250 were enrolled, and of these 15 were excluded from analysis due to invalidity of data. | ||||||||||||||||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Tozorakimab Dose A | ||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants were randomised to receive tozorakimab Dose A by SC injection. | ||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Tozorakimab
|
||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
MEDI3506
|
||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Tozorakimab Dose A by subcutaneous (SC) injection.
|
||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Tozorakimab Dose B | ||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants were randomised to receive tozorakimab Dose B by SC injection. | ||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Tozorakimab
|
||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
MEDI3506
|
||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Tozorakimab Dose B by SC injection.
|
||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||||||||||||||||||||||
Arm description |
Participants were randomised to receive placebo by SC injection. | ||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Placebo by SC injection.
|
||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left. Justification: Two participants in the tozorakimab Dose A arm were not included in the PK population due to no post-baseline PK results. [2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left. Justification: Participants in the placebo arm were not included in the PK population. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Tozorakimab Dose A
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants were randomised to receive tozorakimab Dose A by SC injection. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Tozorakimab Dose B
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants were randomised to receive tozorakimab Dose B by SC injection. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants were randomised to receive placebo by SC injection. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Tozorakimab Dose A
|
||
Reporting group description |
Participants were randomised to receive tozorakimab Dose A by SC injection. | ||
Reporting group title |
Tozorakimab Dose B
|
||
Reporting group description |
Participants were randomised to receive tozorakimab Dose B by SC injection. | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Participants were randomised to receive placebo by SC injection. |
|
|||||||||||||||||
End point title |
Change from Baseline to Week 16 in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in the First Second (FEV1) as Measured in the Study Clinic | ||||||||||||||||
End point description |
In-clinic spirometry measurements were taken prior to the administration of bronchodilators. Baseline was the last measurement prior to first injection of investigational product (IP).
The least squares (LS) means, LS mean differences and 80% confidence intervals (CIs), and one-sided p-value results were based on a mixed model repeated measures (MMRM). The model included fixed effects for baseline, background medication, geographic region, baseline inhaled corticosteroids (ICS) total daily dose, visit, treatment, and the baseline by visit and treatment by visit interactions. Visits within participant were considered as repeated measurements. The ITT population included participants who were randomised and received any study intervention. Participants with data available are included.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Baseline and week 16
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
LS Mean Difference: Tozorakimab Dose B - Placebo | ||||||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
158
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
= 0.473 [1] | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
0.004
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
80% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-0.071 | ||||||||||||||||
upper limit |
0.079 | ||||||||||||||||
Notes [1] - One-sided p-value |
|||||||||||||||||
Statistical analysis title |
LS Mean Difference: Tozorakimab Dose A - Placebo | ||||||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
157
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
= 0.267 [2] | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
0.036
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
80% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-0.038 | ||||||||||||||||
upper limit |
0.111 | ||||||||||||||||
Notes [2] - One-sided p-value |
|
|||||||||||||||||||||||||
End point title |
Change from Baseline to Weeks 8 and 16 in Post-bronchodilator (Post-BD) FEV1 as Measured in the Study Clinic | ||||||||||||||||||||||||
End point description |
In-clinic spirometry measurements were taken following the use of bronchodilators. Bronchodilatation was induced using albuterol (90 µg metered dose), salbutamol (100 µg metered dose), or levalbuterol (45 µg metered dose), and measurements were taken after up to a maximum of 4 inhalations. Baseline was the last measurement prior to first injection of IP.
The LS means, LS mean differences and 80% CIs, and one-sided p-value results were based on MMRM. The model included fixed effects for baseline, background medication, geographic region, baseline ICS total daily dose, visit, treatment, and the baseline by visit and treatment by visit interactions. Visits within participant were considered as repeated measurements. The ITT population included participants who were randomised and received any study intervention. Participants with data available are included.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Baseline and weeks 8 and 16
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Statistical analysis title |
Week 8 Difference: Tozorakimab Dose A - Placebo | ||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||||||||||||||
Number of subjects included in analysis |
59
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||
P-value |
= 0.437 [3] | ||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||||||||||
Point estimate |
-0.012
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
-0.11 | ||||||||||||||||||||||||
upper limit |
0.086 | ||||||||||||||||||||||||
Notes [3] - One-sided p-value |
|||||||||||||||||||||||||
Statistical analysis title |
Week 8 Difference: Tozorakimab Dose B - Placebo | ||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||
P-value |
= 0.221 [4] | ||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||||||||||
Point estimate |
0.059
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
-0.039 | ||||||||||||||||||||||||
upper limit |
0.157 | ||||||||||||||||||||||||
Notes [4] - One-sided p-value |
|||||||||||||||||||||||||
Statistical analysis title |
Week 16 Difference: Tozorakimab Dose A - Placebo | ||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||||||||||||||
Number of subjects included in analysis |
59
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||
P-value |
= 0.308 [5] | ||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||||||||||
Point estimate |
-0.038
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
-0.136 | ||||||||||||||||||||||||
upper limit |
0.06 | ||||||||||||||||||||||||
Notes [5] - One-sided p-value |
|||||||||||||||||||||||||
Statistical analysis title |
Week 16 Difference: Tozorakimab Dose B - Placebo | ||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||
P-value |
= 0.372 [6] | ||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||||||||||
Point estimate |
-0.025
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
-0.122 | ||||||||||||||||||||||||
upper limit |
0.072 | ||||||||||||||||||||||||
Notes [6] - One-sided p-value |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Serum Concentrations of Tozorakimab [7] | ||||||||||||||||||||||||||||||||||||
End point description |
Tozorakimab serum concentrations were measured using a validated assay method. The PK population included participants who received at least one dose of tozorakimab and had at least one detectable serum concentration measurement post-first dose of study intervention. Participants with data available at each time point are presented.
99999 = Geometric mean (CV%) could not be calculated due to too many samples with tozorakimab concentrations below the limit of quantification.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Pharmacokinetic (PK) samples were taken pre-dose (day 1) and at weeks 1, 4, 8, 12, 16, 20, and 24
|
||||||||||||||||||||||||||||||||||||
Notes [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: It was pre-specified for serum concentrations of tozorakimab to be assessed in participants included in the tozorakimab Dose A and tozorakimab Dose B reporting arms only. |
|||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Participants with Anti-drug Antibodies (ADAs) | ||||||||||||||||||||||||||||||||||||||||
End point description |
ADA prevalence is the number of participants ADA positive (ADA+) at baseline (BL) and/or post-BL. Treatment-emergent ADA+ (TE-ADA +) positive is defined as being either of treatment-induced ADA+ (ADA negative [ADA-] at BL and at least one post-BL ADA+) and treatment-boosted ADA+ (ADA+ at BL and BL titre is boosted by ≥ 4-fold increase at ≥ 1 post-BL time point). Treatment-emergent ADA- (TE-ADA-) is defined as ADA+ but not fulfilling the definition of TE-ADA+. ADA persistently positive is defined as ADA- at BL and ADA+ at ≥ 2 post-BL assessment with ≥ 16 weeks between first and last positive assessments, or ADA+ at the last post-BL assessment. ADA transiently positive is defined as ADA- at BL, having at least one post-BL ADA+ assessment and not fulfilling the conditions of ADA persistently positive. BL is defined as the last ADA assessment prior to first injection of IP. The as-treated population included participants who were randomised and received any study intervention.
|
||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Blood samples were taken pre-dose (day 1) and at weeks 1, 4, 8, 12, 16, and 24
|
||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Change from Baseline to Week 16 in the Asthma Control Questionnaire-6 (ACQ-6) Score | ||||||||||||||||
End point description |
In the ACQ-6, participants were asked to recall how their asthma has been during the previous week by responding to one BD-use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). Mean scores of ≤ 0.75 indicate well-controlled asthma, scores between >0.75 and <1.5 indicate partly controlled asthma, and scores ≥1.5 indicate not well-controlled asthma. Results were based on an MMRM which included fixed effects for baseline, background medication, geographic region, baseline ICS total daily dose, visit, treatment and the baseline by visit and treatment by visit interactions. Visits within participant were considered as repeated measurements. A negative change from baseline indicates an improvement in asthma control. The ITT population included participants who were randomised and received any study intervention. Participants with data available are included.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and week 16
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
LS Mean Difference: Tozorakimab Dose B - Placebo | ||||||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
158
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
= 0.371 [8] | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
-0.047
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
80% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-0.231 | ||||||||||||||||
upper limit |
0.137 | ||||||||||||||||
Notes [8] - One-sided p-value |
|||||||||||||||||
Statistical analysis title |
LS Mean Difference: Tozorakimab Dose A - Placebo | ||||||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
157
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
= 0.416 [9] | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||
Point estimate |
-0.03
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
80% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
-0.215 | ||||||||||||||||
upper limit |
0.154 | ||||||||||||||||
Notes [9] - One-sided p-value |
|
|||||||||||||
End point title |
Number of Participants with a Decrease in ACQ-6 Score ≥ 0.5 from Baseline to Week 16 | ||||||||||||
End point description |
In the ACQ-6, participants were asked to recall how their asthma has been during the previous week by responding to one BD-use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). Mean scores of ≤ 0.75 indicate well-controlled asthma, scores between >0.75 and <1.5 indicate partly controlled asthma, and scores ≥1.5 indicate not well-controlled asthma. A decrease in ACQ-6 score baseline indicates an improvement in asthma control, and individual changes of at least 0.5 are considered clinically meaningful. The ITT population included participants who were randomised and received any study intervention. Participants with missing ACQ-6 scores were not included in the analysis.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline and week 16
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Odds Ratio: Tozorakimab Dose B versus Placebo | ||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||
Number of subjects included in analysis |
151
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.348 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
1.41
|
||||||||||||
Confidence interval |
|||||||||||||
level |
80% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.88 | ||||||||||||
upper limit |
2.25 | ||||||||||||
Statistical analysis title |
Odds Ratio: Tozorakimab Dose A versus Placebo | ||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||
Number of subjects included in analysis |
150
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.612 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
1.2
|
||||||||||||
Confidence interval |
|||||||||||||
level |
80% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.76 | ||||||||||||
upper limit |
1.9 |
|
|||||||||||||||||||||||||||||||||
End point title |
Change from Baseline to Week 16 in St George's Respiratory Questionnaire (SGRQ) Domain and Total Scores | ||||||||||||||||||||||||||||||||
End point description |
The SGRQ is a 50-item patient-reported outcome instrument to measure the health status of participants with airway obstruction diseases, giving a total score and 3 domain scores (symptoms, activity, and impacts). The total score is expressed as a percentage of overall impairment, with 100 representing the worst possible health status and 0 the best possible health status. Each domain score ranges from 0 to 100, with higher scores indicating greater impairment. A negative change from baseline indicates an improvement in impairments. Results were based on an MMRM which included fixed effects for baseline, background medication, geographic region, baseline ICS total daily dose, visit, treatment and the baseline by visit and treatment by visit interactions. Visits within participant were considered as repeated measurements. The ITT population included participants who were randomised and received any study intervention. Participants with data available are included.
|
||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||
End point timeframe |
Baseline and week 16
|
||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Statistical analysis title |
SGRQ Activity Score: Tozorakimab Dose A - Placebo | ||||||||||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||||||||||
P-value |
= 0.5 [10] | ||||||||||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||||||||||||||||||
Point estimate |
0.002
|
||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||
lower limit |
-3.825 | ||||||||||||||||||||||||||||||||
upper limit |
3.828 | ||||||||||||||||||||||||||||||||
Notes [10] - One-sided p-value |
|||||||||||||||||||||||||||||||||
Statistical analysis title |
SGRQ Activity Score: Tozorakimab Dose B - Placebo | ||||||||||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
157
|
||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||||||||||
P-value |
= 0.324 [11] | ||||||||||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||||||||||
Parameter type |
Ls mean difference | ||||||||||||||||||||||||||||||||
Point estimate |
-1.364
|
||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||
lower limit |
-5.198 | ||||||||||||||||||||||||||||||||
upper limit |
2.47 | ||||||||||||||||||||||||||||||||
Notes [11] - One-sided p-value |
|||||||||||||||||||||||||||||||||
Statistical analysis title |
SGRQ Impacts Score: Tozorakimab Dose A - Placebo | ||||||||||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||||||||||
P-value |
= 0.248 [12] | ||||||||||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||||||||||||||||||
Point estimate |
-1.421
|
||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||
lower limit |
-4.103 | ||||||||||||||||||||||||||||||||
upper limit |
1.26 | ||||||||||||||||||||||||||||||||
Notes [12] - One-sided p-value |
|||||||||||||||||||||||||||||||||
Statistical analysis title |
SGRQ Impacts Score: Tozorakimab Dose B - Placebo | ||||||||||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
157
|
||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||||||||||
P-value |
= 0.21 [13] | ||||||||||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||||||||||||||||||
Point estimate |
-1.694
|
||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||
lower limit |
-4.383 | ||||||||||||||||||||||||||||||||
upper limit |
0.996 | ||||||||||||||||||||||||||||||||
Notes [13] - One-sided p-value |
|||||||||||||||||||||||||||||||||
Statistical analysis title |
SGRQ Symptoms Score: Tozorakimab Dose A - Placebo | ||||||||||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||||||||||
P-value |
= 0.42 [14] | ||||||||||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||||||||||||||||||
Point estimate |
0.691
|
||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||
lower limit |
-3.715 | ||||||||||||||||||||||||||||||||
upper limit |
5.096 | ||||||||||||||||||||||||||||||||
Notes [14] - One-sided p-value |
|||||||||||||||||||||||||||||||||
Statistical analysis title |
SGRQ Symptoms Score: Tozorakimab Dose B - Placebo | ||||||||||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
157
|
||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||||||||||
P-value |
= 0.181 [15] | ||||||||||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||||||||||||||||||
Point estimate |
-3.15
|
||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||
lower limit |
-7.579 | ||||||||||||||||||||||||||||||||
upper limit |
1.28 | ||||||||||||||||||||||||||||||||
Notes [15] - One-sided p-value |
|||||||||||||||||||||||||||||||||
Statistical analysis title |
SGRQ Total Score: Tozorakimab Dose A - Placebo | ||||||||||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||||||||||
P-value |
= 0.38 [16] | ||||||||||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||||||||||||||||||
Point estimate |
-0.663
|
||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||
lower limit |
-3.454 | ||||||||||||||||||||||||||||||||
upper limit |
2.129 | ||||||||||||||||||||||||||||||||
Notes [16] - One-sided p-value |
|||||||||||||||||||||||||||||||||
Statistical analysis title |
SGRQ Total Score: Tozorakimab Dose B - Placebo | ||||||||||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||||||||||||||||||||||
Number of subjects included in analysis |
157
|
||||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||||||||||
P-value |
= 0.192 [17] | ||||||||||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||||||||||||||||||
Point estimate |
-1.896
|
||||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||||||||||
lower limit |
-4.694 | ||||||||||||||||||||||||||||||||
upper limit |
0.903 | ||||||||||||||||||||||||||||||||
Notes [17] - One-sided p-value |
|
|||||||||||||
End point title |
Number of Participants Achieving ACQ-6 Well Controlled Status at Week 16 | ||||||||||||
End point description |
In the ACQ-6, participants were asked to recall how their asthma has been during the previous week by responding to one BD-use question and 5 symptom questions. Questions were weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). Mean scores of ≤ 0.75 indicate well-controlled asthma, scores between >0.75 and <1.5 indicate partly controlled asthma, and scores ≥1.5 indicate not well-controlled asthma. The ITT population included participants who were randomised and received any study intervention. Participants with missing ACQ-6 scores were not included in the analysis.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline and week 16
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Odds Ratio: Tozorakimab Dose B versus Placebo | ||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||
Number of subjects included in analysis |
151
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.679 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
0.86
|
||||||||||||
Confidence interval |
|||||||||||||
level |
80% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.53 | ||||||||||||
upper limit |
1.38 | ||||||||||||
Statistical analysis title |
Odds Ratio: Tozorakimab Dose A versus Placebo | ||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||
Number of subjects included in analysis |
150
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.575 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
0.81
|
||||||||||||
Confidence interval |
|||||||||||||
level |
80% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.5 | ||||||||||||
upper limit |
1.31 |
|
|||||||||||||
End point title |
Number of Participants with a Decrease in SGRQ Total Score of ≥ 4 Points from Baseline to Week 16 | ||||||||||||
End point description |
The SGRQ is a 50-item patient-reported outcome instrument to measure the health status of participants with airway obstruction diseases, giving a total score and 3 domain scores (symptoms, activity, and impacts). The total score is expressed as a percentage of overall impairment, with 100 representing the worst possible health status and 0 the best possible health status. A decrease in the SGRQ total score indicates an improvement in overall impairment. The ITT population included participants who were randomised and received any study intervention. Participants with missing SGRQ scores were not included in the analysis.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline and week 16
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Odds Ratio: Tozorakimab Dose B versus Placebo | ||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||
Number of subjects included in analysis |
151
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.84 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
1.07
|
||||||||||||
Confidence interval |
|||||||||||||
level |
80% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.68 | ||||||||||||
upper limit |
1.7 | ||||||||||||
Statistical analysis title |
Odds Ratio: Tozorakimab Dose A versus Placebo | ||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||
Number of subjects included in analysis |
150
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.828 | ||||||||||||
Method |
Chi-squared | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
0.93
|
||||||||||||
Confidence interval |
|||||||||||||
level |
80% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.59 | ||||||||||||
upper limit |
1.46 |
|
|||||||||||||||||
End point title |
Asthma CompEx Annualised Event Rate | ||||||||||||||||
End point description |
The annualised rate of asthma CompEx events was calculated as the total number of asthma CompEx events / (date of last dose of IP + 28 - date of first dose of IP - recovery time + 1) / 365.25.
The rates, rate ratios, and one-sided p-values were estimated from a negative binomial regression, with the log(follow up time) included as an offset term. The dependent variable will be the number of CompEx events during the on-treatment period (i.e., from baseline to last dose date +28 days), and the model will include treatment group, background medication, geographic region and baseline ICS total daily dose as covariates. The ITT population included participants who were randomised and received any study intervention.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline to week 16
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Rate Ratio: Tozorakimab Dose B versus Placebo | ||||||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
158
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
= 0.166 [18] | ||||||||||||||||
Method |
Negative binomial regression | ||||||||||||||||
Parameter type |
Rate ratio | ||||||||||||||||
Point estimate |
0.7
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
80% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
0.43 | ||||||||||||||||
upper limit |
1.12 | ||||||||||||||||
Notes [18] - One-sided p-value |
|||||||||||||||||
Statistical analysis title |
Rate Ratio: Tozorakimab Dose A versus Placebo | ||||||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
158
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
= 0.346 [19] | ||||||||||||||||
Method |
Negative binomial regression | ||||||||||||||||
Parameter type |
Rate ratio | ||||||||||||||||
Point estimate |
0.87
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
80% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
0.56 | ||||||||||||||||
upper limit |
1.36 | ||||||||||||||||
Notes [19] - One-sided p-value |
|
|||||||||||||
End point title |
Number of Participants for Time to First Asthma CompEx Event | ||||||||||||
End point description |
Asthma CompEx is a combination of exacerbations of asthma and diary events (i.e., a combination of electronic diary [eDiary] variables). eDiary events are defined by criteria using morning/evening diary variables of PEF, symptoms, and use of rescue medication. A participant was considered to have a CompEx event if they had one or both of an asthma exacerbation or diary event. For participants who did not experience an on-treatment CompEx event, date of censoring was the minimum between the date of last dose + 28 days, and the last day of eDiary recording during the on-treatment period. Time to first Asthma CompEx event was calculated as [start date of first event or censoring - date of first dose] + 1. The ITT population included participant who were randomised and received any study intervention.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline to week 16
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Hazard Ratio: Tozorakimab Dose B versus Placebo | ||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||
Number of subjects included in analysis |
158
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.461 [20] | ||||||||||||
Method |
Regression, Cox | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
1
|
||||||||||||
Confidence interval |
|||||||||||||
level |
80% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.6 | ||||||||||||
upper limit |
1.7 | ||||||||||||
Notes [20] - One-sided p-value estimated using a Cox regression model with treatment group, background medication, geographic region, and ICS total daily dose as covariates. |
|||||||||||||
Statistical analysis title |
Hazard Ratio: Tozorakimab Dose A versus Placebo | ||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||
Number of subjects included in analysis |
158
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
superiority | ||||||||||||
P-value |
= 0.239 [21] | ||||||||||||
Method |
Regression, Cox | ||||||||||||
Parameter type |
Hazard ratio (HR) | ||||||||||||
Point estimate |
1.3
|
||||||||||||
Confidence interval |
|||||||||||||
level |
80% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.8 | ||||||||||||
upper limit |
2 | ||||||||||||
Notes [21] - One-sided p-value estimated using a Cox regression model with treatment group, background medication, geographic region, and ICS total daily dose as covariates. |
|
|||||||||||||||||
End point title |
Percent Change from Baseline to Week 16 in Concentration of Fractional Exhaled Nitric Oxide (FeNO) in Exhaled Breath | ||||||||||||||||
End point description |
A standardised single-breath FeNO test was performed to evaluate airway inflammation. Results were based on MMRM on log-transformed change from baseline. Log-transformed change from baseline
is calculated as the visit value in log minus the baseline value in log. The results from the model were then back transformed. The model included fixed effects for baseline (in log), background medication, geographic region, baseline ICS total daily dose, visit, treatment and the baseline by visit and treatment by visit interactions. Visits within subject were considered as repeated measurements.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline and week 16
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Geometric LS Mean Ratio | ||||||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
158
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
= 0.04 [22] | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Geometric LS mean ratio | ||||||||||||||||
Point estimate |
0.879
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
80% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
0.8 | ||||||||||||||||
upper limit |
0.966 | ||||||||||||||||
Notes [22] - One-sided p-value |
|||||||||||||||||
Statistical analysis title |
Geometric LS Mean Ratio | ||||||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||||||
Number of subjects included in analysis |
155
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority | ||||||||||||||||
P-value |
= 0.029 [23] | ||||||||||||||||
Method |
MMRM | ||||||||||||||||
Parameter type |
Geometric LS Mean Ratio | ||||||||||||||||
Point estimate |
0.869
|
||||||||||||||||
Confidence interval |
|||||||||||||||||
level |
80% | ||||||||||||||||
sides |
2-sided
|
||||||||||||||||
lower limit |
0.791 | ||||||||||||||||
upper limit |
0.956 | ||||||||||||||||
Notes [23] - One-sided p-value |
|
|||||||||||||||||||||||||
End point title |
Eosinophil Count | ||||||||||||||||||||||||
End point description |
The eosinophil count at baseline and week 16 are presented. Baseline was defined as the last measurement prior to first injection of IP.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Baseline and Week 16
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Statistical analysis title |
Week 16 Geometric LS Mean Ratio | ||||||||||||||||||||||||
Statistical analysis description |
Tozorakimab Dose B versus Placebo
|
||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||||||||||||||
Number of subjects included in analysis |
158
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||
P-value |
< 0.001 [24] | ||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||
Parameter type |
Geometric LS Mean Ratio | ||||||||||||||||||||||||
Point estimate |
0.675
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
0.599 | ||||||||||||||||||||||||
upper limit |
0.76 | ||||||||||||||||||||||||
Notes [24] - One-sided p-value |
|||||||||||||||||||||||||
Statistical analysis title |
Week 16 Geometric LS Mean Ratio | ||||||||||||||||||||||||
Statistical analysis description |
Tozorakimab Dose A versus Placebo
|
||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||||||||||||||
Number of subjects included in analysis |
158
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
superiority [25] | ||||||||||||||||||||||||
P-value |
< 0.001 [26] | ||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||
Parameter type |
Geometric LS Mean Ratio | ||||||||||||||||||||||||
Point estimate |
0.63
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
0.559 | ||||||||||||||||||||||||
upper limit |
0.71 | ||||||||||||||||||||||||
Notes [25] - A total of 156 participants were included in this analysis. [26] - One-sided p-value |
|
|||||||||||||||||||||||||
End point title |
Change from Baseline to Week 16 in Pre-BD FEV1 as Measured in the Study Clinic: Analysis per Number of Exacerbations in Last 12 Months | ||||||||||||||||||||||||
End point description |
In-clinic spirometry measurements were taken prior to the administration of bronchodilators. Baseline was the last measurement prior to first injection of IP.
The LS means, LS mean differences and 80% CIs, and one-sided p-value results were based on MMRM. The model included fixed effects for baseline, visit, treatment, and the baseline by visit and treatment by visit interactions. Visits within participant were considered as repeated measurements. Analysis is presented by the number of exacerbations experienced within the 12 months prior to baseline (1 or ≥ 2 exacerbations in the previous 12 months). The ITT population included participants who were randomised and received any study intervention.
|
||||||||||||||||||||||||
End point type |
Other pre-specified
|
||||||||||||||||||||||||
End point timeframe |
Baseline and week 16
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Statistical analysis title |
LS Mean Difference: Tozorakimab Dose A - Placebo | ||||||||||||||||||||||||
Statistical analysis description |
Analysis of treatment difference in participants with 1 exacerbation in the last 12 months.
|
||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||||||||||||||
Number of subjects included in analysis |
97
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||
P-value |
= 0.385 [27] | ||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||||||||||
Point estimate |
0.023
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
-0.078 | ||||||||||||||||||||||||
upper limit |
0.124 | ||||||||||||||||||||||||
Notes [27] - One-sided p-value; alpha = 0.1 |
|||||||||||||||||||||||||
Statistical analysis title |
LS Mean Difference: Tozorakimab Dose A - Placebo | ||||||||||||||||||||||||
Statistical analysis description |
Analysis of treatment difference in participants with ≥ 2 exacerbations in the last 12 months.
|
||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose A v Placebo
|
||||||||||||||||||||||||
Number of subjects included in analysis |
97
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
superiority [28] | ||||||||||||||||||||||||
P-value |
= 0.186 [29] | ||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||||||||||
Point estimate |
0.077
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
-0.034 | ||||||||||||||||||||||||
upper limit |
0.187 | ||||||||||||||||||||||||
Notes [28] - A total of 90 participants were included in this analysis. [29] - One-sided p-value; alpha = 0.1 |
|||||||||||||||||||||||||
Statistical analysis title |
LS Mean Difference: Tozorakimab Dose B - Placebo | ||||||||||||||||||||||||
Statistical analysis description |
Analysis of treatment difference in participants with ≥ 2 exacerbations in the last 12 months.
|
||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||||||||||||||
Number of subjects included in analysis |
99
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
superiority [30] | ||||||||||||||||||||||||
P-value |
= 0.007 [31] | ||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||||||||||
Point estimate |
0.212
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
0.102 | ||||||||||||||||||||||||
upper limit |
0.322 | ||||||||||||||||||||||||
Notes [30] - A total of 90 participants were included in this analysis. [31] - One-sided p-value; alpha = 0.1 |
|||||||||||||||||||||||||
Statistical analysis title |
LS Mean Difference: Tozorakimab Dose B - Placebo | ||||||||||||||||||||||||
Statistical analysis description |
Analysis of treatment difference in participants with 1 exacerbation in the last 12 months.
|
||||||||||||||||||||||||
Comparison groups |
Tozorakimab Dose B v Placebo
|
||||||||||||||||||||||||
Number of subjects included in analysis |
99
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||
P-value |
= 0.06 [32] | ||||||||||||||||||||||||
Method |
MMRM | ||||||||||||||||||||||||
Parameter type |
LS mean difference | ||||||||||||||||||||||||
Point estimate |
-0.123
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
80% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
-0.224 | ||||||||||||||||||||||||
upper limit |
-0.022 | ||||||||||||||||||||||||
Notes [32] - One-sided p-value; alpha = 0.1 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Day 1 to Week 24 (up to 24 weeks)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
25.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Tozorakimab Dose A
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants were randomised to receive tozorakimab Dose A by SC injection. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Tozorakimab Dose B
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants were randomised to receive tozorakimab Dose B by SC injection. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants were randomised to receive placebo by SC injection. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
19 Oct 2020 |
- Removal of references to the interim analysis for the study.
- Removal of airway volume and airway resistance computed tomography (CT) scan measures from airway remodelling endpoint.
- Addition of study stopping criteria.
- Removal of reference of relatedness of serious adverse events as a reason to discontinue participants from the study and 'any SAE of ≥ Grade 4 severity' added.
- Addition of new discontinuation criterion
- Severity rating scale for adverse events updated to a Grade 1 to 5 based on Common Terminology Criteria for Adverse Events (CTCAE). |
||
23 Feb 2021 |
- Addition of provision for increased flexibility during the screening period, for clinical laboratory testing due to practical limitation in receiving test results.
- Addition of provision for increased flexibility for COVID-19 PCR testing during the screening period due to practical limitation in receiving test results.
- Clarification that all female participants should have had a pregnancy test.
- Addition of provision for retesting of interferon gamma release assay (IGRA).
- Provision of clarification to investigators of the sponsor's approach to COVID-19 vaccination in this study.
- Addition of provision for retesting of N-terminal prohormone of B-type natriuretic peptide (NT-proBNP).
- Adjustment to the periods to which the adherence criteria applied.
- Addition of allowance that limited personnel that had responsibility for PK and ADA sample analysis could have access to the randomisation schedule.
- Clarification that adenoviral vector vaccines were not considered live attenuated.
- Addition of restriction on when vaccines against COVID-19 may have been administered, and clarification on the requirement to record COVID-19 vaccination. |
||
25 May 2021 |
- To amend study endpoints as appropriate for the change to a 2-part study design.
- To amend the study design to include 2 parts: Part A (main study) and Part B (airway hyperresponsiveness and remodelling study).
- Specified that post-BD spirometry was to be performed if documented evidence of asthma was not already available.
- Clarification that on days when IP was administered, all assessments should have been performed pre-dose unless otherwise specified.
- Provision of clarity on pregnancy testing in female participants.
- Clarification of provision for airwave oscillometry and in-clinic spirometry to be performed 4 hours post-administration of study intervention at randomisation.
- Specified that the mean value of each parameter from the triplicate electrocardiogram was to be used as the baseline value.
- Clarification of the doses of tozorakimab used in Part A.
- Clarification of a positive IGRA test in the context of treated latent tuberculosis infection.
- Clarification of eligibility criteria relating to history of asthma exacerbations and the use of systemic corticosteroids.
- Clarified that assessment of injection site reactions after administration of study intervention was carried out by a blinded study team.
- Updated list of medication withhold periods to be applied prior to scheduled spirometry, airway oscillometry, and FeNO measurement.
- Updated information to be recorded if and when a participant received a COVID-19 vaccination.
- Changed 'congenital abnormality' to 'congenital anomaly'.
- Specified that ADA samples may have been tested for neutralising antibodies. |
||
08 Mar 2022 |
- Removal of references to and text regarding Part B, and removal of occurrences of 'Part A' as Part B had been removed and Part A was the entirety of the study.
- Addition of text to minimise any missing mandatory samples.
- Updated rationale for risk of progression of heart failure.
- Changes to the inclusion criteria to increase the permitted body mass index, and historic exacerbation requirement from one in 12 months to one in 24 months.
- Changes to the exclusion criteria to remove the exclusion of all participants who tested positive for SARS-CoV-2 at the first screening visit, and all participants who tested positive at the second screening visit continued to be excluded; to remove the exclusion of participants with NT-proBNP above the upper limit of normal; and to remove reference to HbA1c in relation to the control of type 2 diabetes.
- Removed dose from list of information to be recorded for COVID-19 vaccination.
- Adjustment of requirements of acceptable documentation of historical asthma exacerbations.
- Aligned with EU guidelines for data storage. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
15 participants at 1 study centre were excluded from the final analysis due to inability to confirm the validity of the data. This did not change the interpretation of the primary endpoint or for any other endpoint. |